NASDAQ$SUPN
Supernus Pharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Supernus Pharmaceuticals, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting significant growth in Qelbree and GOCOVRI sales, improved operating earnings, and the FDA approval of ONAPGO.
Supernus Pharmaceuticals reported a strong fourth quarter and full year 2024, driven by substantial increases in Qelbree and GOCOVRI net product sales. Total revenues for Q4 2024 reached $174.2 million, with operating earnings of $21.4 million and diluted EPS of $0.27. The company also announced the FDA approval of ONAPGO, with a planned launch in Q2 2025.
- Fourth quarter 2024 net sales of Qelbree increased 60% to $74.4 million, compared to the same period in 2023.
- Fourth quarter 2024 net sales of GOCOVRI increased 15% to $36.9 million, compared to the same period in 2023.
- Operating earnings for the fourth quarter of 2024 were $21.4 million, a significant improvement from an operating loss of $(1.0) million in the same period in 2023.
- ONAPGO (apomorphine hydrochloride) was approved by the U.S. Food and Drug Administration and is set to launch in the second quarter of 2025.
Headline financials
Revenue & EPS history
Supernus · Revenue · Quarterly
$174M
Revenue by segment
Supernus · $50.2M total across 2 segments · Q3 2023
- Oxtellar XR$29.6M-3.0%59.0%
- Trokendi XR$20.6M-70.4%41.0%
Forward guidance
For the full year 2025, Supernus Pharmaceuticals expects total revenues to be between $600 million and $630 million, with operating earnings (loss) ranging from $(15) million to $10 million, and adjusted operating earnings (non-GAAP) between $105 million and $130 million.
Tailwinds
- Continued Qelbree growth is expected.
- Launch of ONAPGO for Parkinson's disease is planned for the second quarter of 2025.
- Further advancement of the product pipeline.
- Adjusted operating earnings (non-GAAP) are projected to be positive, ranging from $105 million to $130 million.
- The company anticipates generating cash from operations.
Headwinds
- Total revenues are projected to decrease compared to FY 2024.
- Operating earnings are projected to be a loss, ranging from $(15) million to $10 million.
- Continued generic erosion of Trokendi XR is expected.
- Generic erosion of Oxtellar XR is expected to begin in September 2024.
- Combined R&D and SG&A expenses are projected to be between $435 million and $460 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.1%
Avg return
30 days after
48%
27 / 56 earnings
Positive
+22.3%
Q3 2020
Best reaction
-29.9%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +6.1% | -8.1% | |
| Q4 2025 | +7.9% | +0.7% | +0.1% | |
| Q3 2025 | -16.9% | -20.4% | -19.9% | |
| Q1 2025 | -4.6% | -0.9% | +2.2% | |
| Q4 2024 | -2.7% | -3.3% | -1.6% | |
| Q3 2024 | +2.3% | +7.7% | +9.4% | |
| Q2 2024 | +14.3% | +15.0% | +23.1% | |
| Q1 2024 | -3.7% | -4.7% | -15.7% | |
| Q4 2023 | +5.4% | +5.1% | +15.6% | |
| Q3 2023 | +9.6% | +14.5% | +12.8% | |
| Q2 2023 | -5.3% | -1.1% | -6.8% | |
| Q1 2023 | -0.2% | -7.2% | -3.3% | |
| Q4 2022 | +3.4% | +4.8% | -4.5% | |
| Q3 2022 | -5.9% | +0.9% | +2.5% | |
| Q2 2022 | +0.4% | -3.1% | +7.4% | |
| Q1 2022 | -6.0% | -2.5% | +2.7% | |
| Q4 2021 | -3.1% | -8.7% | -16.5% | |
| Q3 2021 | +5.0% | +11.6% | +1.1% | |
| Q2 2021 | -1.1% | -4.3% | +2.1% | |
| Q1 2021 | -2.7% | -2.5% | -0.7% | |
| Q4 2020 | -13.2% | -12.1% | -11.3% | |
| Q3 2020 | +22.3% | +28.4% | +18.5% | |
| Q2 2020 | -6.0% | -12.5% | -9.7% | |
| Q1 2020 | +4.7% | +4.3% | +7.8% | |
| Q4 2019 | -18.5% | -6.6% | -17.7% | |
| Q3 2019 | -29.9% | -23.6% | -22.8% | |
| Q2 2019 | -11.8% | -11.5% | -14.0% | |
| Q1 2019 | -7.0% | -5.0% | -20.3% | |
| Q4 2018 | +12.8% | +2.2% | -0.6% | |
| Q3 2018 | +8.4% | +8.6% | -2.8% | |
| Q2 2018 | -8.1% | -12.9% | -13.6% | |
| Q1 2018 | +6.3% | +26.5% | +20.2% | |
| Q4 2017 | +0.0% | +1.9% | +17.7% | |
| Q3 2017 | -13.4% | -11.4% | -13.3% | |
| Q2 2017 | +3.1% | +4.1% | +17.2% | |
| Q1 2017 | +0.0% | +4.2% | +28.7% | |
| Q4 2016 | -2.4% | -1.1% | +9.5% | |
| Q3 2016 | +5.1% | +10.2% | +11.1% | |
| Q2 2016 | +3.2% | +4.0% | -0.9% | |
| Q1 2016 | -5.7% | — | — | |
| Q4 2015 | +7.8% | — | — | |
| Q3 2015 | +6.0% | — | — | |
| Q2 2015 | -8.9% | — | — | |
| Q1 2015 | -7.1% | — | — | |
| Q4 2014 | +11.1% | — | — | |
| Q3 2014 | +4.1% | — | — | |
| Q2 2014 | +7.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +9.8% | — | — | |
| Q3 2013 | +9.5% | — | — | |
| Q2 2013 | +6.8% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | -22.6% | — | — | |
| Q3 2012 | +2.8% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q1 2012 | -5.9% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro